mAbxience |

Meet us at BIO International Convention 2018

05/30/2018

From 4th to 7th June, the BIO International Convention 2018 will take place in Boston, hosted by the Biotechnology Innovation Organization (BIO). This event attracts 16,000+ biotechnology and pharma leaders covering a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy. Our business development and commercial […]

mAbxience and Amneal enter into an agreement 
for bevacizumab biosimilar in the United States


05/23/2018

The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment.

Biosimilars reduce healthcare costs by up to 40% and increase patient accessibility to innovative treatments

05/07/2018

These medicinal products are similar to their counterparts in terms of efficacy, safety and quality, and are backed by comprehensive clinical studies Cancer treatments are some of the ones that benefit the most from this medical innovation, and at a lower price for Health Authorities Treatments with biosimilar medicinal products mean that more patients are […]

5th Castilla y León’s Best Director Awards

04/30/2018

On the occasion of the awards granted by Castilla y León Económica magazine for the fifth year, Luisa Amoedo, director of mAbxience León, has been awarded as Best Export / Internationalization Director. The jury of the 5th Castilla y León’s Best Director Awards is composed of José María Ribot García, General Manager of Instituto para […]

Cancer Chemotherapy and Pharmacology has published comparative data of rituximab biosimilar RTXM83R in lymphoma patients

03/06/2018

The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83™ rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients.  The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity […]

2nd National Conference on Biosimilars

03/05/2018

mAbxience actively participated in the 2nd National Conference on Biosimilars organised by the Spanish Biosimilar Medicines Association, BioSim. The conference, entitled “Biosimilars: evidence and efficiency”, took place at the Ministry of Health, Social Services and Equality in Madrid on 21st February. Francisco Olivera, Operations Manager at mAbxience León, shared the “Evidence: from R&D to authorisation” […]